Heidelberg Pharma AG (ETR:HPHA)

Market Cap	124.91M -15.4%
Revenue (ttm)	3.22M -53.0%
Net Income	-40.62M
EPS	-0.87
Shares Out	46.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,689
Open	2.720
Previous Close	2.690
Day's Range	2.670 - 2.720
52-Week Range	2.330 - 5.360
Beta	0.74
Analysts	Buy
Price Target	5.50 (+105.99%)
Earnings Date	Jul 15, 2026

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company’s lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 111
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: HPHA

Financial Performance

In fiscal year 2025, Heidelberg Pharma AG's revenue was 1.46 million, a decrease of -78.72% compared to the previous year's 6.85 million. Losses were -42.28 million, 118.1% more than in 2024.